医药针对临床适应证的目标定位趋势：1930-2013 年。
Trends in pharmaceutical targeting of clinical indications: 1930-2013.
机构信息
Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA.
Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA.
出版信息
Drug Discov Today. 2014 Nov;19(11):1682-1685. doi: 10.1016/j.drudis.2014.05.021. Epub 2014 May 29.
An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications. Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs. Infectious diseases are the most targeted indications. Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased. The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined. By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications. These results suggest the drug development community has largely been responsive to public health and market needs. However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.
对 FDA 批准的新型实体（NME）的分析揭示了治疗应用的趋势。四个分组（传染病、心血管疾病、自身免疫/炎症性疾病和癌症）占 NME 的 60%以上。传染病是最受关注的适应症。在新千年之交，传染病新批准的速度下降。针对精神科、神经科和疼痛/瘙痒适应症的 NME 的绝对数量和相对数量也有所下降。相比之下，过去二十年中针对癌症的 NME 以及针对孤儿适应症的 NME 有所增加。这些结果表明，药物开发界在很大程度上对公共卫生和市场需求做出了反应。然而，有限的资源可能表明，对某些未满足需求的重视可能会以牺牲其他需求为代价。
Zotero 插件